ArticleFrontiers in immunology2026
Fc-mediated antibody functions are associated with disease severity in COVID-19.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Fc-mediated antibody effector functions play key roles in both antiviral immunity and immunopathology in COVID-19. While antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) contribute to pathogen clearance, they may also be associated with inflammatory responses. The contribution of these pathways-particularly antibody-dependent enhancement (ADE)-to severe COVID-19 remains incompletely understood. We prospectively investigated relationships among ADE, ADCC, and ADCP across multiple SARS-CoV-2 variants from 64 patients with laboratory-confirmed SARS-CoV-2 infection. Methods: Patient Fc-mediated effector activities were profiled. Disease severity was classified using National Institutes of Health criteria. ADE was assessed using pseudotyped SARS-CoV-2 entry into THP-1 cells, whereas Fc gamma receptors (FcγR)IIIa- and FcγRIIa-mediated reporter activities (reflecting ADCC and ADCP surrogate responses, respectively) were assessed using spike-expressing A549 target cells and FcγR-expressing Jurkat-Lucia reporter cells. Functional responses were measured against wild-type SARS-CoV-2 and Omicron sublineages (B.1.1.529, BA.4/BA.5, XBB.1.5). Results: Among 64 participants (40 with mild, 24 with severe COVID-19; median age, 58 years [interquartile range, 45-71], 56% men), anti-spike IgG binding did not differ by severity. ADE activity was significantly higher in severe than mild COVID-19 and remained independently associated with severity in multivariable analysis. FcγRIIa-mediated reporter activity was higher in severe cases in descriptive and univariate analyses, but lost statistical significance after adjustment for age, sex, comorbidities, and variant period. FcγRIIIa-mediated reporter activity did not differ by severity but was reduced against Omicron variants. Plasma from severe cases promoted enhanced FcγR-dependent viral entry in pseudovirus assays; yet, subsequent live Omicron virus infection did not lead to an increase in viral RNA replication-consistent with an abortive infection without evidence of productive viral replication. Conclusion: Our findings suggest that ADE activity is associated with dysregulated Fc-mediated immune responses in severe COVID-19. Although multiple Fcγ receptor-mediated pathways were observed, the independent association of ADE with disease severity supports a potential link with excessive FcγR-mediated myeloid activation. FcγRIIa reporter activity likely reflects overlapping immune signatures rather than an independent pathogenic contribution, whereas FcγRIIIa reporter activity showed no clear relationship with clinical outcomes. These findings highlight the complexity of Fc-effector immunity and support further investigation into therapeutic strategies targeting Fc-FcγR interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.